Source comparison
Kisspeptin for PCOS Research: Full Comparison
Primary mechanism Blocks hypothalamic estrogen receptors to disinhibit GnRH Inhibits aromatase to lower estrogen and increase FSH Directly stimulates GnRH neurons to restore pulse frequency Kisspeptin acts upstream of feedback loops. Mechanistically superior f
This comparison does not assign a generated winner or score.
- Primary mechanism
- Blocks hypothalamic estrogen receptors to disinhibit GnRH
- Inhibits aromatase to lower estrogen and increase FSH
- Directly stimulates GnRH neurons to restore pulse frequency
- Kisspeptin acts upstream of feedback loops. Mechanistically superior for neuroendocrine dysfunction
- Efficacy in lean PCOS
- 60–70% ovulation rate
- 65–75% ovulation rate
- 58% ovulation rate (12-week protocol, Phase 2)
- Comparable short-term efficacy but limited long-term data
- Efficacy in obese PCOS
- 40–50% ovulation rate
- 50–60% ovulation rate
- <20% ovulation rate without insulin sensitizer co-treatment
- Kisspeptin shows significant phenotype dependence. Fails in metabolic PCOS
- Route of administration
- Oral tablet, 5 days per cycle
- Subcutaneous infusion, 6–8 hours twice weekly
- Oral dosing far more practical. Kisspeptin delivery remains a major barrier
- Receptor desensitization risk
- None. Acts via estrogen receptor blockade
- None. Acts via enzyme inhibition
- High. Continuous KISS1R activation downregulates receptor
- Long-term kisspeptin use may lose efficacy unless dosed in pulses
- Cost (research setting)
- $30–$50 per cycle
- $40–$60 per cycle
- $2,000–$3,000 per 12-week protocol (investigational pricing)
- Kisspeptin cost will drop if approved, but oral SERMs remain far cheaper